Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 251

Results For "Mark"

5379 News Found

Granules India receives ANDA approval for Trazodone Tablets
Drug Approval | August 11, 2024

Granules India receives ANDA approval for Trazodone Tablets

Trazodone tablets are indicated for the treatment of major depressive disorder in adults


IOL Chemicals and Pharmaceuticals posts Q1 FY25 PAT at Rs. 29.7 Cr
News | August 10, 2024

IOL Chemicals and Pharmaceuticals posts Q1 FY25 PAT at Rs. 29.7 Cr

The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24


Biocon posts Q1 FY25 PAT higher at Rs. 660 Cr
News | August 10, 2024

Biocon posts Q1 FY25 PAT higher at Rs. 660 Cr

This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.


Atul Bioscience received EIR from USFDA for Ambernath facility
Drug Approval | August 09, 2024

Atul Bioscience received EIR from USFDA for Ambernath facility

The EIR was issued post the last inspection of the facility conducted from May 6-10, 2024 which concluded with zero FDA 483 observations


Balaji Amines Q4 FY25 revenue stood at Rs. 393 Cr
News | August 08, 2024

Balaji Amines Q4 FY25 revenue stood at Rs. 393 Cr

The pharma market is showing encouraging signs of improvement, positioning us well for future growth


JB Pharma records Q1 FY25 PAT higher by 25% to Rs. 177 Cr
News | August 08, 2024

JB Pharma records Q1 FY25 PAT higher by 25% to Rs. 177 Cr

Expect the international business including CDMO business to pick-up in the second half of the financial year


Sucralose safe to use in small doses; reveals MDRF study
News | August 07, 2024

Sucralose safe to use in small doses; reveals MDRF study

Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers


Bayer Group posts 2Q 2024 sales up 3.1% at € 11.14 billion
News | August 07, 2024

Bayer Group posts 2Q 2024 sales up 3.1% at € 11.14 billion

Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings


India emerging as world-class cost-effective healthcare destination and global pharma leader: Dr. Jitendra Singh
Policy | August 07, 2024

India emerging as world-class cost-effective healthcare destination and global pharma leader: Dr. Jitendra Singh

He advocated for a "PPP + PPP" collaboration, urging the public and private sectors within India to partner with their counterparts in other countries